Page last updated: 2024-11-02

pd 98059 and Pulmonary Hypertension

pd 98059 has been researched along with Pulmonary Hypertension in 2 studies

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source
2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gao, H1
Cheng, Y1
Zong, L1
Huang, L1
Qiao, C1
Li, W1
Gong, B1
Hu, J1
Liu, H1
Wang, X1
Zhao, C1
Yu, L1
Quinn, DA1
Garg, HG1
Hales, CA1

Other Studies

2 other studies available for pd 98059 and Pulmonary Hypertension

ArticleYear
Aspirin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing the ERK/MAPK pathway.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2017, Volume: 39, Issue:1

    Topics: Animals; Aspirin; Blood Pressure; Cyclooxygenase Inhibitors; Flavonoids; Hypertension, Pulmonary; Hy

2017
Gene expression of cyclin-dependent kinase inhibitors and effect of heparin on their expression in mice with hypoxia-induced pulmonary hypertension.
    Biochemical and biophysical research communications, 2006, Jul-14, Volume: 345, Issue:4

    Topics: Animals; Cell Cycle Proteins; Cells, Cultured; Cyclin D2; Cyclin-Dependent Kinase 2; Cyclin-Dependen

2006